Radioprotectant for peptides labeled with radioisotope
AssigneeCoulter Pharmaceutical, Inc.
InventorsDan Shochat, Albert S. K. Chan, Michael J. Buckley, David Colcher
Life of this patent
Estimating the term…
Abstract
A method of ameliorating degradation of radiolabeled peptides, especially radiolabeled proteins such as antibodies, by including povidone, also widely known as polyvinylpyrrolidone or PVP, as a radioprotectant in a composition containing a radiolabeled peptide is described. A radioprotectant composition and a stable peptide-radioisotope composition having povidone are also described. Ascorbic acid or other secondary stabilizers may also be added to the compositions to further enhance radioprotection.
Claims81
A stable peptide-radioisotope composition comprising:
- a radiolabeled peptide, and
- povidone, wherein the povidone is present in an amount sufficient to ameliorate degradation of the peptide by radioactivity.
A method for ameliorating degradation of a composition including a radiolabeled peptide, the method comprising:
- contacting povidone with the composition.
A radioprotectant for radiolabeled peptides comprising:
- a stabilizer solution capable of being contacted with a radiolabeled peptide, wherein the stabilizer solution comprises povidone and a secondary stabilizer selected from the group consisting of ascorbic acid, benzyl alcohol, cysteamine, cystamine, proplene glycol, dextran, and gentisic acid.
A method for making a stable peptide-radioisotope composition, the method comprising:
- labeling a peptide with a radioisotope, and
- contacting the labeled peptide with povidone immediately after the labeling step.
A composition comprising:
- anti-CD20 antibody radiolabeled with .sup.131 I, the antibody being present in a concentration of 1.5-2.5 mg/ml of the composition and the .sup.131 I having a radioactivity level of 8-12 mCi,
- povidone in a concentration of 5-6% w/v of the composition, and
- ascorbic acid in a concentration of 0.9-1.3 mg/ml of the composition.
A composition comprising:
- anti-CD20 antibody radiolabeled with .sup.131 I, the antibody being present in a concentration of 1.5-2.5 mg/ml of the composition and the .sup.131 I having a radioactivity level of 112-166 mCi,
- povidone in a concentration of 5-6% w/v of the composition, and
- ascorbic acid in a concentration of 0.9-1.3 mg/ml of the composition.
An article of manufacture comprising:
- a stabilizer including povidone, and
- instructions for using the stabilizer to ameliorate degradation of a radiolabeled peptide by radioactivity by contacting the stabilizer to the radiolabeled peptide.
Dependencies are inferred from the claim text.